TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22943848
Drug: Conventional lit-end
Normalized name: End-Zit
DrugBank: Octasulfur (DB09353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional lit-end cigarettes (CC)
Study: 18498913
Drug: Single-dose memantine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose memantine 5 mg
Study: 18498913
Drug: Single-dose memantine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose memantine 10 mg
Study: 18498913
Drug: Single-dose memantine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose memantine 20 mg
Study: 18498913
Drug: Multiple-dose memantine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-dose memantine 5 mg once daily for 14 days
Study: 15941893
Drug: Glutamine supplementation
Normalized name: Glutamine
DrugBank: L-Glutamine (DB00130)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glutamine supplementation (0.3 g . kg(‐1) . d(‐1))
Study: 10562579
Drug: Sulindac 150
Normalized name: sulindac 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac 150 mg orally twice a day for three months (n=10)
Study: 8712447
Drug: Epidural clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural clonidine (targeted to 50, 100, 200, or 400 ng/ml)
Study: 8712447
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of neostigmine and clonidine
Study: 1910342
Drug: FCH-free, NTG-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCH-free, NTG-containing spray (0.8 mg NTG)
Study: 1910342
Drug: FCH- and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCH- and NTG-containing spray (0.8 mg NTG)
Study: 1910342
Drug: Placebo (FCH-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (FCH- and NTG-free spray, 2 puffs)
Study: 25238031
Drug: Full-arch implant-fixed
Normalized name: arched swimming crab, cooked preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-arch implant-fixed prostheses (G1)
Study: 25238031
Drug: Multiple implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple implant splinting via acrylic resin denture bases (G2)
Study: 22944060
Drug: Domestic rosuvastatin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Domestic rosuvastatin, 10 mg/day
Study: 22944060
Drug: CRESTOR, 10
Normalized name: Crestor, 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRESTOR, 10 mg/day
Study: 11915378
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green (ICG) 12.5 mg
Study: 11915378
Drug: Indocyanine green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Indocyanine green (ICG) 25 mg
Study: 9793701
Drug: Subcutaneous sumatriptan
Normalized name: Sumatriptan
DrugBank: Sumatriptan (DB00669)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous sumatriptan for treating migraine attacks
Study: 1977980
Drug: Antibiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic treatment (metronidazole 20 mg/kg or 5 mg/kg daily, amoxycillin 25 mg/kg daily)
Study: 28976
Drug: 1.0 mg
Normalized name: HYDROCORTISONE BUTYRATE 1.0 mg in 1 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 mg 15(S)15-methyl PGF2alpha methyl ester pessaries every 3 hours (maximum 4 doses)
Study: 28976
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg 15(S)15-methyl PGF2alpha methyl ester pessaries every 3 hours (maximum 4 doses)
Study: 28976
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses (1.0 mg and 1.5 mg)
Study: 31788995
Drug: 4-weekly carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4-weekly carboplatin area under the curve 4 and pegylated liposomal doxorubicin (PLD) 30 mg/m², n=24
Study: 31788995
Drug: 4-weekly carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4-weekly carboplatin area under curve 4 and pegylated liposomal doxorubicin (PLD) 30 mg/m², n=24
Study: 12745614
Drug: Intrathecal BDNF
Normalized name: BDNF, human
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal BDNF therapy
Study: 10784225
Drug: Human soluble
Normalized name: Recombinant human soluble insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human soluble insulin (Humulin S)
Study: 1329477
Drug: Once-daily lisinopril
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily lisinopril (5-20 mg)
Study: 1329477
Drug: Twice-daily captopril
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily captopril (12.5-50 mg)
Study: 28042578
Drug: Aromatherapy (inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aromatherapy (inhalation of a blend of 1.0 mL of lemon and 0.5 mL of ginger essential oils)
Study: 28042578
Drug: Control (inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (inhalation of distilled water as placebo)
Study: 22274951
Drug: Palonosetron 0.25
Normalized name: palonosetron 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 0.25 mg intravenously on days 1 and 4 (schedule 1)
Study: 22274951
Drug: Palonosetron 0.25
Normalized name: palonosetron 0.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palonosetron 0.25 mg intravenously on days 1, 3, and 5 (schedule 2)
Study: 22274951
Drug: Both dosing
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosing schedules of palonosetron
Study: 20637970
Drug: Avanafil 50
Normalized name: avanafil 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avanafil 50 mg
Study: 20637970
Drug: Avanafil (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avanafil (all doses)
Study: 19099009
Drug: GW406381 (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW406381 (1, 5, 10, 25, or 50 mg)
Study: 16400293
Drug: Newer drugs
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Newer drugs (lamotrigine, levetiracetam, topiramate, zonisamide)
Study: 16400293
Drug: Drug combinations,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug combinations, vagal nerve stimulation, felbamate
Study: 9430449
Drug: Human corticotropin-releasing
Normalized name: Human corticotropin-releasing factor
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human corticotropin-releasing hormone (hCRH) 2.0 microg/kg i.v.
Study: 9430449
Drug: Hexarelin (HEX)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexarelin (HEX) and AVP co-administration
Study: 9430449
Drug: Hexarelin (HEX)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexarelin (HEX) and hCRH co-administration
Study: 9430449
Drug: CRH and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRH and AVP co-administration
Study: 8495455
Drug: Propranolol LA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol LA 80 mg once daily
Study: 8495455
Drug: Propranolol LA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol LA 160 mg once daily
Study: 3003166
Drug: Water Pik
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water Pik oral irrigator
Study: 25218827
Drug: Gabapentin 900
Normalized name: gabapentin 900 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 900 mg + Donepezil 5 mg
Study: 22931620
Drug: Oral intestinal
Normalized name: pork intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intestinal probiotics (Jinshuangqi Tablets, 2.0 g, 3 times daily)
Study: 22931620
Drug: Oral intestinal
Normalized name: pork intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral intestinal antimicrobial agents
Study: 17240625
Drug: Anagrelide treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anagrelide treatment
Study: 8861742
Drug: Minocycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minocycline (100 mg twice a day)
Study: 1462746
Drug: 5‐FU alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5‐FU alone (440 mg/m2 IV bolus 5/21 days)
Study: 1462746
Drug: Folinic acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic acid (200 mg/m2 IV bolus 5/21 days) preceding 5‐FU (370 mg/m2 in short infusion 5/21 days)
Study: 1462746
Drug: Immediate post‐operative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate post‐operative continuous portal infusion (5‐FU 500 mg/m2/day x 7 followed by a 2 hours infusion of mitomycin C 10 mg/m2)
Study: 31412688
Drug: Consumption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consumption of vegetables (41.28 g per portion at T0)
Study: 31412688
Drug: Consumption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consumption of vegetables (36.67 g per portion at T1)
Study: 31412688
Drug: Consumption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consumption of fruit (15.25 g per portion at T1)
Study: 31412688
Drug: Healthy Eating
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy Eating Index (39.26 g per 10 points at T0)
Study: 31412688
Drug: Healthy Eating
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy Eating Index (42.76 g per 10 points at T1)
Study: 31412688
Drug: Sugar-sweetened beverages
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar-sweetened beverages (10.90 g per portion at T0)
Study: 31412688
Drug: Sugar-sweetened beverages
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar-sweetened beverages (8.19 g per portion at T1)
Study: 31412688
Drug: Higher sugar
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher sugar consumption at T0 (8.27 g per 10 g)
Study: 31412688
Drug: Early pregnancy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early pregnancy alcohol intake (15.32 g per g)
Study: 26509229
Drug: 1×15 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1×15 minutes application of 35% hydrogen peroxide gel
Study: 26509229
Drug: 2×15 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2×15 minutes application of 35% hydrogen peroxide gel
Study: 26509229
Drug: 3×15 minutes
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3×15 minutes application of 35% hydrogen peroxide gel
Study: 10085475
Drug: 0.6 mg/cm2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.6 mg/cm2 melatonin applied 15 min before UV irradiation
Study: 8536413
Drug: Absolute leucocyte
Normalized name: Honey Absolute
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absolute leucocyte differential counts (cells x 10(9)/l)
Study: 1703769
Drug: Secondary CHOP
Normalized name: Secondary potassium phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary CHOP treatment
Study: 1703769
Drug: Secondary CisEBP
Normalized name: Secondary potassium phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Secondary CisEBP treatment
Study: 31474260
Drug: Fixed palatal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed palatal crib (FPC) treatment (TG)
Study: 23356210
Drug: ASKP1240 (0.00003‐10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASKP1240 (0.00003‐10 mg/kg)
Study: 20137402
Drug: Intrarectal lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrarectal lidocaine gel plus PNB (Group C)
Study: 18196620
Drug: rosuvastatin 10
Normalized name: rosuvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 10 mg once daily
Study: 18196620
Drug: atorvastatin 10
Normalized name: atorvastatin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atorvastatin 10 mg once daily
Study: 15071604
Drug: alemtuzumab (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: alemtuzumab (30 mg i.v. TIW, 12 weeks)
Study: 1671346
Drug: Immediate intravenous
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate intravenous metoprolol (15 mg IV over 6 minutes, followed by 50 mg orally every 12 hours for 24 hours, then 100 mg orally every 12 hours)
Study: 1671346
Drug: Deferred metoprolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferred metoprolol (50 mg orally twice on day 6, then 100 mg orally twice a day thereafter)
Study: 6883915
Drug: Zomepirac (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zomepirac (400 mg and 800 mg)
Study: 6883915
Drug: Morphine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine (15 mg and 30 mg)
Study: 26314234
Drug: Control (contrast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (contrast agent)
Study: 22459201
Drug: 0.42 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.42 mg/kg d‐methamphetamine
Study: 20458441
Drug: Enoxaparin 80
Normalized name: ENOXAPARIN 80MG/0.8ML INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin 80 mg
Study: 17122975
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of virtual reality training and inanimate box training
Study: 16115831
Drug: Two intramuscular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two intramuscular doses of 12 mg betamethasone in the 48 hours before delivery
Study: 8640466
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral hydration (sips of fruit juices sweetened with honey, solid food 24 hours later)
Study: 8640466
Drug: Conventional intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intravenous hydration (2-3 L of dextrose saline/24 hours, solid food thereafter)
Study: 8640466
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral hydration
Study: 2174277
Drug: Regimens including
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regimens including radiotherapy after chemotherapy
Study: 30056127
Drug: Single-dose 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose 0.5% ropivacaine paravertebral block (PVB) with patient-controlled intravenous analgesia (PCIA)
Study: 30056127
Drug: Single-dose 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose 0.5% ropivacaine and dexmedetomidine (1 μg/kg) PVB with PCIA
Study: 30056127
Drug: Intraoperative thoracic
Normalized name: Thoracol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraoperative thoracic epidural anesthesia with 0.5% ropivacaine and single dose of epidural morphine (0.03 mg/kg) with PCIA
Study: 25250722
Drug: Low-dose intravenous
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose intravenous immunoglobulins (IVIG) treatment
Study: 22708798
Drug: Aminolaevulinate photodynamic
Normalized name: aminolevulinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aminolaevulinate photodynamic therapy (PDT)
Study: 21698545
Drug: NY‐ESO‐1 protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: NY‐ESO‐1 protein with ISCOMATRIX™ adjuvant (10 μg, 30 μg, or 100 μg)
Study: 21698545
Drug: 100 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 μg un‐adjuvanted NY‐ESO‐1 protein
Study: 21698545
Drug: 2 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 μg DTH protein
Study: 21698545
Drug: DTH skin
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTH skin testing with NY‐ESO‐1 protein (1 μg) or peptides (10 μg)
Study: 17415632
Drug: Antibiotics as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics as adjunct therapy to conventional treatment (corticosteroids and 5-aminosalycilic acid)
Study: 17415632
Drug: Antibiotics (short-term
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (short-term trials of 5-14 days)
Study: 10216089
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus 300 mg vitamin E twice daily (n = 9)
Study: 10216089
Drug: In vitro
Normalized name: glucuronidase in vitro test
Approvals — FDA: no, EMA: no, PMDA: no
Description: In vitro vitamin E (50 micromol/L)
Study: 10216089
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (n = 5)
Study: 8848526
Drug: Bretazenil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bretazenil (1 mg)
Study: 28457318
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (4.4 g daily providing 2.6 g eicosapentaenoic acid and 1.8 g docosahexaenoic acid)
Study: 23934907
Drug: Well-functioning implants
Approvals — FDA: no, EMA: no, PMDA: no
Description: Well-functioning implants
Study: 23934907
Drug: Sub-optimal functioning
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sub-optimal functioning implants
Study: 20647959
Drug: Hormone therapy
Normalized name: INVESTIGATIONAL HORMONE THERAPY/REPLACEMENT,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hormone therapy (HT) users with CRP levels of 3 mg/L or higher
Study: 20647959
Drug: Nonusers with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonusers with CRP levels of 3 mg/L or higher
Study: 19662783
Drug: Budesonide/formoterol (640
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide/formoterol (640 mcg of budesonide and 18 mcg of formoterol daily)
Study: 8948369
Drug: Nucleoside or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nucleoside or non-nucleoside analog reverse transcriptase inhibitors
Study: 8948369
Drug: Combination nucleoside
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination nucleoside analog therapy
Study: 8948369
Drug: Ritonavir (HIV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritonavir (HIV protease inhibitor) monotherapy
Study: 6185222
Drug: Tiapamil (0.3-1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapamil (0.3-1.5 mg/kg bolus doses)
Study: 6185222
Drug: Tiapamil (12-25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapamil (12-25 mg/h continuous infusion)
Study: 6185222
Drug: Tiapamil (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiapamil (1 mg/kg)
Study: 6185222
Drug: Verapamil (0.13
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (0.13 mg/kg)
Study: 29848343
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (Trauma‐focused Music and Imagery, TMI)
Study: 29848343
Drug: Verbal psychotherapy
Normalized name: HERBAL MISCELLANEOUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verbal psychotherapy (standard treatment)
Study: 18315426
Drug: SDD-40 (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDD-40 (40 mg doxycycline, once daily)
Study: 17060062
Drug: olmesartan 20
Normalized name: olmesartan 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: olmesartan 20 mg plus glibenclamide 3.5 mg
Study: 17060062
Drug: glibenclamide 3.5
Normalized name: Glibenclamide 3.5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: glibenclamide 3.5 mg
Study: 11426360
Drug: Intravenous milrinone
Normalized name: Milrinone
DrugBank: Milrinone (DB00235)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous milrinone (50 microg/kg during 10 minutes followed by 0.5 microg/kg/min)
Study: 11426360
Drug: Intravenous dobutamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dobutamine (10 to 20 microg/kg/min)
Study: 8435895
Drug: Continuous 24-hour
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous 24-hour infusion of 2 IU GH
Study: 8435895
Drug: Two intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two intravenous boluses of 2 IU GH
Study: 8435895
Drug: Eight intravenous
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eight intravenous boluses of 2 IU GH every 3 hours
Study: 8435895
Drug: Single subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single subcutaneous injection of 0.2 U/kg GH
Study: 18450928
Drug: Neurocognition and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurocognition and symptom measures during treatment
Study: 12637464
Drug: Arzoxifene 20
Normalized name: Arzoxifene
DrugBank: Arzoxifene (DB06249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arzoxifene 20 mg
Study: 12637464
Drug: Arzoxifene 50
Normalized name: Arzoxifene
DrugBank: Arzoxifene (DB06249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arzoxifene 50 mg
Study: 11131781
Drug: Second dose
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second dose of oral misoprostol (400 microg)
Study: 19843783
Drug: Intrathecal 10
Normalized name: LIORESAL INTRATHECAL 10 MG in 20 ML (500 MCG/ML) Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal 10 mg lidocaine 2% plus 10 microg fentanyl (Group I)
Study: 19843783
Drug: Intrathecal 3
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal 3 mg levobupivacaine 0.5% plus 10 microg fentanyl (Group II)
Study: 17199533
Drug: Autologous fibroblast
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous fibroblast injections
Study: 15262418
Drug: Nystatin incorporated
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nystatin incorporated into gel and suspension formulations
Study: 15262418
Drug: Chitosan gel
Normalized name: Chitosan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chitosan gel alone
Study: 15262418
Drug: Nystatin formulations
Normalized name: Nystatin
DrugBank: Nystatin (DB00646)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nystatin formulations
Study: 9609412
Drug: Enteral ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enteral ciprofloxacin 750 mg b.i.d.
Study: 9609412
Drug: Intravenous ciprofloxacin
Normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ciprofloxacin 400 mg b.i.d.
Study: 3185292
Drug: Conjugated oestrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated oestrogens 1.25 mg
Study: 3185292
Drug: Oestradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oestradiol valerate 2 mg
Study: 31230222
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment of donepezil hydrochloride and choline supplement